Plain-English translation of NCT07391657 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial compares a new treatment called — a type of therapy that uses your own immune cells reprogrammed to fight cancer — against standard chemotherapy drugs for multiple myeloma that has returned or stopped responding to earlier treatments. Researchers want to see if this personalized cell therapy works better and is safer than the current standard approach. The study will enroll about 500 patients across multiple hospitals worldwide.
Multiple myeloma is a blood cancer that often comes back or stops responding to initial treatments, leaving patients with limited options. This medication represents a newer approach that harnesses the body's own immune system, and researchers hope it may be more effective and offer longer-lasting results than the traditional drug combinations currently used.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will be randomly assigned to receive either the new cell therapy or one of four standard chemotherapy drug combinations (your doctor will help determine which is best for you). You will visit the hospital regularly for treatment, monitoring, and blood tests. The exact schedule depends on which treatment arm you're in, but expect ongoing visits over many months as researchers track how well the treatment works and watch for any side effects.
AI-generated summary from trial data · Jul 5, 2026 · Not medical advice
United States